Stock 605116 AURISCO PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Aurisco Pharmaceutical Co.,Ltd. Stock

Equities

605116

CNE1000042S4

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
22.75 CNY +0.49% Intraday chart for Aurisco Pharmaceutical Co.,Ltd. +2.52% -11.89%
2023 Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
2023 Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2023. CI

Financials

Sales 2023 * 1.32B 183M Sales 2024 * 1.69B 234M Capitalization 9.24B 1.28B
Net income 2023 * 300M 41.44M Net income 2024 * 389M 53.73M EV / Sales 2023 * 6.99 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 5.47 x
P/E ratio 2023 *
31 x
P/E ratio 2024 *
23.7 x
Employees 1,355
Yield 2023 *
-
Yield 2024 *
-
Free-Float 16.75%
More Fundamentals * Assessed data

Chart Aurisco Pharmaceutical Co.,Ltd.

Dynamic Chart

Latest news about Aurisco Pharmaceutical Co.,Ltd.

Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2023. CI
Aurisco Pharmaceutical Co.,Ltd.(XSSC:605116) added to S&P Global BMI Index CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Aurisco Pharmaceutical Gets Auxiton(R) (Dydrogesterone) as First Generic Approval in China CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Aurisco Cooperates with Cytiva to Build Its First Oligo Flexfactory for Commercial Production CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2022. CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Huayi Boao Quantum Technology Co., Ltd. announced that it has received CNY 100 million in funding from Aurisco Pharmaceutical Co.,Ltd., Gaorong Capital, Sequoia China Investment Management LLP, Turing Ventures, Qiji Chuangtan Investment Management Co., Ltd. CI
Huayi Quantum announced that it has received CNY 15.5 million in funding from Gaorong Capital, Sequoia China Investment Management LLP, Qiji Chuangtan Investment Management Co., Ltd., Turing Ventures, Aurisco Pharmaceutical Co.,Ltd. CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
More news

Quotes and Performance

1 day+0.49%
1 week+2.52%
Current month+3.22%
1 month-0.70%
3 months-3.60%
6 months+1.43%
Current year-11.89%
More quotes

Highs and lows

1 week
21.20
Extreme 21.2
23.19
1 month
21.20
Extreme 21.2
23.49
Current year
17.33
Extreme 17.33
26.50
1 year
17.33
Extreme 17.33
27.58
3 years
12.14
Extreme 12.14
31.22
5 years
10.04
Extreme 10.04
31.22
10 years
10.04
Extreme 10.04
31.22
More quotes

Managers and Directors - Aurisco Pharmaceutical Co.,Ltd.

Managers TitleAgeSince
Ding Jun Chu CEO
 Chief Executive Officer 51 17-05-31
Xiu Yu Wang DFI
 Director of Finance/CFO 43 17-05-31
De Fa Zhang CTO
 Chief Tech/Sci/R&D Officer 51 17-05-31
Members of the board TitleAgeSince
Yong Cheng Zhong BRD
 Director/Board Member 60 23-05-04
Wei Ke Su BRD
 Director/Board Member 63 23-05-04
Zhi An Peng CHM
 Chairman 51 16-05-31
More insiders

Quotes

Date Price Change Volume
24-04-19 22.75 +0.49% 1,443,950
24-04-18 22.64 +1.98% 2,161,850
24-04-17 22.2 +3.06% 1,309,918
24-04-16 21.54 -1.33% 1,578,726
24-04-15 21.83 -1.62% 1,288,500

End-of-day quote Shanghai S.E., April 18, 2024

More quotes

Company Profile

Aurisco Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of specialty active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The Company's main products are respiratory, cardiovascular, anti-infective and nervous system drugs, including flumethasone, fluticasone propionate, eplerenone, tenofovir, pregabalin and other APIs and intermediates. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-28 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Aurisco Pharmaceutical Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
22.75 CNY
Average target price
31 CNY
Spread / Average Target
+36.26%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
AURISCO PHARMACEUTICAL CO.,LTD. Stock Aurisco Pharmaceutical Co.,Ltd.
-11.89% 1.27B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+24.60% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.08% 550B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.63% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.37% 317B
ABBVIE INC. Stock AbbVie Inc.
+7.38% 292B
ASTRAZENECA PLC Stock AstraZeneca PLC
+3.26% 211B
NOVARTIS AG Stock Novartis AG
+0.78% 203B
PFIZER, INC. Stock Pfizer, Inc.
-9.69% 144B
AMGEN INC. Stock Amgen Inc.
-6.63% 141B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 605116 Stock